Dengue Fever: Protecting Employees and Families from a Year-Round Threat
Dengue fever is one of the most common mosquito-borne diseases in the Philippines. Transmitted by the Aedes aegypti mosquito, dengue affects thousands of Filipinos every year—often during rainy months but increasingly throughout the year due to changing climate and urban conditions.
For companies, dengue can have serious operational consequences: extended absences, hospitalizations, and rising HMO utilization. While environmental control and hygiene remain important, vaccination now offers an added layer of protection for both employees and their dependents.
Understanding Dengue and Its Impact
Dengue is caused by four distinct but related viruses (DEN-1 to DEN-4). Infection by one type does not guarantee immunity to others—meaning a person can be infected multiple times.
Symptoms include:
- Sudden high fever
- Severe headache and joint pain (“break-bone fever”)
- Muscle pain, nausea, or vomiting
- Skin rashes appearing after several days of fever
- In some cases, bleeding gums, bruising, or internal hemorrhage
While most patients recover, severe dengue can lead to Dengue Hemorrhagic Fever (DHF) or Dengue Shock Syndrome (DSS), both potentially fatal. Hospitalization and recovery can take 1 to 2 weeks, often longer for complicated cases.
Workplace Relevance: The Cost of Dengue to Businesses
Infections can strike employees at any level, from field workers to office professionals, causing:
- Absenteeism of 7–14 days or more per case
- Decreased productivity due to post-illness fatigue
- Increased healthcare costs and HMO reimbursements
- Secondary infections among family members, leading to multiple absences
In high-density cities like Metro Manila and Cebu, dengue outbreaks can disrupt operations and stretch company medical resources. Preventive vaccination helps businesses maintain continuity and employee wellbeing even during peak dengue season.
Prevention Through Dengue Vaccination
Alongside environmental control (mosquito elimination, repellents, and protective clothing), vaccination now plays a vital role in dengue prevention.
Available Dengue Vaccines:
- Dengvaxia® (Sanofi Pasteur): Approved for individuals 9 to 45 years old with a documented history of prior dengue infection.
- Qdenga® (Takeda): A newer generation vaccine recently approved in several countries, offering broader protection for individuals 4 years and older, regardless of prior infection status (availability in the Philippines pending local regulatory rollout).
Recommended Schedule:
- Dengvaxia®: Three doses, administered six months apart.
- Qdenga®: Two doses, three months apart (once fully available locally).
Vaccination significantly reduces the risk of hospitalization and severe dengue, particularly for those previously exposed to the virus—common among Filipino adults.
Who Should Be Vaccinated
Dengue vaccination is recommended for:
- Employees aged 9–45 years old with prior dengue infection.
- Frequent travelers or workers assigned to high-risk provinces.
- Field personnel, sales teams, and construction workers exposed to outdoor environments.
- Dependents—especially school-aged children, who are among the most vulnerable groups.
Even a single dengue episode in a family can create both emotional strain and financial stress. Company-sponsored vaccination helps safeguard both employees and their households.
Corporate Benefits of Dengue Vaccination
Implementing a dengue vaccination program brings measurable benefits to organizations:
- Reduced absenteeism and productivity loss during outbreak months.
- Lower HMO and hospitalization costs through disease prevention.
- Improved workforce morale by showing commitment to employee health.
- Enhanced corporate image as a socially responsible, health-conscious employer.
- Complementary protection alongside existing environmental safety programs.
Preventing one severe dengue case costs far less than hospitalization, medical reimbursements, or lost workdays.
Extending Protection to Dependents
Progressive companies now include dengue vaccination in family wellness programs—either subsidized or optional.
Protecting dependents helps:
- Build herd protection within households.
- Reduce employee absenteeism from caregiving duties.
- Control corporate medical spending linked to dengue outbreaks.
- Foster a stronger sense of loyalty and wellbeing among staff.
A healthy family supports a healthy workforce, and contributes to sustained productivity.
Corporate Dengue Vaccination by Affinity Vaccines
Affinity Vaccines provides corporate dengue vaccination programs for organizations across the Philippines.
Our Corporate Program Management Team ensures a safe, efficient, and fully compliant vaccination process:
- Evaluation of employee eligibility and risk profiles.
- Transparent vaccine cost proposals.
- On-site medical team deployment and cold-chain management.
- Post-vaccination observation and documentation.
We can also combine dengue vaccination with Flu, Pneumonia, Hepatitis, and Tdap drives as part of an integrated workplace wellness campaign.
Current Status of Dengue Vaccines in the Philippines
While dengue vaccination remains one of the most promising strategies for long-term disease control, it is important to understand the current regulatory landscape in the Philippines.
The first dengue vaccine, Dengvaxia® (Sanofi Pasteur), was withdrawn from local public use several years ago following safety concerns regarding its administration to individuals who had never been infected with dengue. The product remains approved in other countries but is no longer part of the Philippine government’s immunization programs.
A newer and more advanced vaccine, Qdenga® (Takeda), has since been developed and approved in several countries, including those with high dengue burden such as Thailand, Indonesia, and Brazil.
As of this time, Qdenga® is still undergoing regulatory evaluation in the Philippines and is not yet commercially available. However, there is growing anticipation within the medical and public health community for its eventual approval, given its potential to provide broader protection against dengue for both seropositive and seronegative individuals.
Affinity Vaccines continues to monitor updates from the Philippine Food and Drug Administration (FDA) and the Department of Health (DOH) regarding Qdenga® and other dengue vaccine developments. Once approved and available locally, we aim to make these vaccines accessible to corporate clients and their employees through our managed workplace immunization programs.
Protect Your People. Protect Your Business. Strengthen Your Organization.
Dengue remains a year-round threat, but one that can be prevented.
Affinity Vaccines offers corporate immunization programs for organizations that value health and prevention. Whether you need dengue vaccination (once available), flu shots, or a comprehensive workplace immunization campaign, our Corporate Program Management Team will contact you, understand your requirements, propose vaccine costs, and arrange a professional medical team to ensure every dose is administered safely and efficiently.
📩 Request for a Corporate Vaccination Proposal
To inquire or request a corporate vaccination proposal, contact:
Email: vaccines@affinity.com.ph